APLENZIN Drug Patent Profile
✉ Email this page to a colleague
When do Aplenzin patents expire, and what generic alternatives are available?
Aplenzin is a drug marketed by Bausch and is included in one NDA. There are eight patents protecting this drug and three Paragraph IV challenges.
This drug has fifty-three patent family members in eighteen countries.
The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the bupropion hydrobromide profile page.
DrugPatentWatch® Generic Entry Outlook for Aplenzin
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be June 27, 2026. This may change due to patent challenges or generic licensing.
There are three Paragraph IV patent challenges for this drug. This may lead to patent invalidation or a license for generic production.
There is one tentative approval for the generic drug (bupropion hydrobromide), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
Summary for APLENZIN
International Patents: | 53 |
US Patents: | 8 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 18 |
Clinical Trials: | 2 |
Patent Applications: | 3,620 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for APLENZIN |
What excipients (inactive ingredients) are in APLENZIN? | APLENZIN excipients list |
DailyMed Link: | APLENZIN at DailyMed |



DrugPatentWatch® Estimated Generic Entry Opportunity Date for APLENZIN
Generic Entry Date for APLENZIN*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, EXTENDED RELEASE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for APLENZIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Valeant Pharmaceuticals International, Inc. | Phase 4 |
Bausch Health Americas, Inc. | Phase 4 |
SRI International | Phase 4 |
Pharmacology for APLENZIN
Drug Class | Aminoketone |
Mechanism of Action | Dopamine Uptake Inhibitors Norepinephrine Uptake Inhibitors |
Physiological Effect | Increased Dopamine Activity Increased Norepinephrine Activity |
Anatomical Therapeutic Chemical (ATC) Classes for APLENZIN
Paragraph IV (Patent) Challenges for APLENZIN
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
APLENZIN | Extended-release Tablets | bupropion hydrobromide | 522 mg | 022108 | 1 | 2009-12-24 |
APLENZIN | Extended-release Tablets | bupropion hydrobromide | 174 mg | 022108 | 1 | 2009-09-28 |
APLENZIN | Extended-release Tablets | bupropion hydrobromide | 348 mg | 022108 | 1 | 2009-09-24 |
US Patents and Regulatory Information for APLENZIN
APLENZIN is protected by eight US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of APLENZIN is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting APLENZIN
Modified release formulations of a bupropion salt
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Modified release formulations of a bupropion salt
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS
Modified release formulations of a bupropion salt
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Modified release formulations of a bupropion salt
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Bupropion hydrobromide and therapeutic applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Modified release formulations of a bupropion salt
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Modified release formulations of a bupropion salt
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Bupropion hydrobromide and therapeutic applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch | APLENZIN | bupropion hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 022108-001 | Apr 23, 2008 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Bausch | APLENZIN | bupropion hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 022108-003 | Apr 23, 2008 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Bausch | APLENZIN | bupropion hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 022108-003 | Apr 23, 2008 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for APLENZIN
When does loss-of-exclusivity occur for APLENZIN?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 06261788
Estimated Expiration: See Plans and Pricing
Patent: 08285660
Estimated Expiration: See Plans and Pricing
Patent: 08320915
Estimated Expiration: See Plans and Pricing
Canada
Patent: 78626
Estimated Expiration: See Plans and Pricing
Patent: 55596
Estimated Expiration: See Plans and Pricing
Patent: 99588
Estimated Expiration: See Plans and Pricing
Patent: 00733
Estimated Expiration: See Plans and Pricing
China
Patent: 1534808
Estimated Expiration: See Plans and Pricing
Patent: 1784266
Estimated Expiration: See Plans and Pricing
Patent: 1903016
Estimated Expiration: See Plans and Pricing
Colombia
Patent: 51360
Estimated Expiration: See Plans and Pricing
Patent: 70385
Estimated Expiration: See Plans and Pricing
Costa Rica
Patent: 09
Estimated Expiration: See Plans and Pricing
Patent: 259
Estimated Expiration: See Plans and Pricing
Ecuador
Patent: 077999
Estimated Expiration: See Plans and Pricing
Patent: 109923
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 96002
Estimated Expiration: See Plans and Pricing
Patent: 32124
Estimated Expiration: See Plans and Pricing
Patent: 85139
Estimated Expiration: See Plans and Pricing
Patent: 14650
Estimated Expiration: See Plans and Pricing
Patent: 74308
Estimated Expiration: See Plans and Pricing
Patent: 02621
Estimated Expiration: See Plans and Pricing
Hong Kong
Patent: 42811
Estimated Expiration: See Plans and Pricing
Israel
Patent: 5760
Estimated Expiration: See Plans and Pricing
Patent: 8989
Estimated Expiration: See Plans and Pricing
Japan
Patent: 95615
Estimated Expiration: See Plans and Pricing
Patent: 08546841
Estimated Expiration: See Plans and Pricing
Patent: 10535740
Estimated Expiration: See Plans and Pricing
Patent: 11500865
Estimated Expiration: See Plans and Pricing
Mexico
Patent: 10001449
Estimated Expiration: See Plans and Pricing
Patent: 10003872
Estimated Expiration: See Plans and Pricing
New Zealand
Patent: 1375
Estimated Expiration: See Plans and Pricing
Patent: 2925
Estimated Expiration: See Plans and Pricing
Nicaragua
Patent: 1000015
Estimated Expiration: See Plans and Pricing
Patent: 1000044
Estimated Expiration: See Plans and Pricing
Russian Federation
Patent: 08368
Estimated Expiration: See Plans and Pricing
Patent: 85942
Estimated Expiration: See Plans and Pricing
Patent: 85943
Estimated Expiration: See Plans and Pricing
Patent: 07147343
Estimated Expiration: See Plans and Pricing
Patent: 10107843
Estimated Expiration: See Plans and Pricing
Patent: 10116863
Estimated Expiration: See Plans and Pricing
Singapore
Patent: 3695
Estimated Expiration: See Plans and Pricing
South Africa
Patent: 0711123
Estimated Expiration: See Plans and Pricing
Patent: 1000425
Estimated Expiration: See Plans and Pricing
Patent: 1003036
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 1306635
Estimated Expiration: See Plans and Pricing
Patent: 080026098
Estimated Expiration: See Plans and Pricing
Patent: 100055402
Estimated Expiration: See Plans and Pricing
Patent: 100077182
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering APLENZIN around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Russian Federation | 2485943 | БУПРОПИОНА ГИДРОБРОМИД И ЕГО ТЕРАПЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ (BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS THEREOF) | See Plans and Pricing |
Colombia | 6270385 | BROMHIDRATO DE BUPROPION Y APLICACIONES TERAPEUTICAS | See Plans and Pricing |
World Intellectual Property Organization (WIPO) | 2009056550 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for APLENZIN
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2316456 | 349 22-2017 | Slovakia | See Plans and Pricing | PRODUCT NAME: KOMBINACIA NALTREXONU VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM A BUPROPIONU VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/14/988 20150330 |
2316456 | 2017/059 | Ireland | See Plans and Pricing | PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/14/988 20150326 |
0656775 | CR 2000 00018 | Denmark | See Plans and Pricing | PRODUCT NAME: BUPROPIONHYDROCHLORID; NAT. REG. NO/DATE: 31347 20000606; FIRST REG. NO/DATE: NL 24160 19991201 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |